Karmanos Selected for Multiple Myeloma Research Consortium's Clinical Research Network
Tuesday, December 06, 2011
The Barbara Ann Karmanos Cancer Institute was recently selected as part of the Multiple Myeloma Research Consortium (MMRC) clinical research network. Following a rigorous evaluation, the Karmanos Cancer Institute, one of 40 National Cancer Institute-designated comprehensive cancer centers in the nation, joins the existing MMRC member institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.
Jeffrey Zonder, M.D.
“We are proud to join such a highly respected model for accelerating the development of new treatment options for multiple myeloma patients,” said Jeffrey Zonder, M.D., associate professor of Medicine and Oncology, Karmanos Cancer Institute and Wayne State University School of Medicine. “We are looking forward to collaborating with the MMRC, its elite member institutions, and its partners in the biotech and pharmaceutical industries to bring patients the next generation of multiple myeloma treatments.”
As an MMRC member institution, Karmanos will participate in all clinical research activities of the Consortium, including the conduction of Phase I and II clinical trials of promising myeloma treatments. In this role, Karmanos will also contribute multiple myeloma patient tissue samples to the MMRC Tissue Bank, a cutting-edge resource that bridges laboratory and clinical research.
"We are pleased to welcome the Karmanos Cancer Institute to the MMRC's esteemed clinical network," said Beverly Harrison, vice president, Clinical Development. "Like all MMRC Member Institutions, Karmanos was selected to join this exclusive network based on its outstanding reputation for clinical excellence, its demonstrated commitment to rigorous research, and its true spirit of collaboration and team-science. We have no doubt that Karmanos will prove to be an invaluable asset in our efforts to rapidly shepherd the next generation of treatments through the MMRC."
For information on the Karmanos Cancer Institute’s multiple myeloma clinical trials, contact Silvana Pregja at 313-576-8673 or email email@example.com